Weight-loss jabs could cut the risk of breast cancer by nearly a third, according to a landmark study presented at the American Society of Clinical Oncology conference.

A study of 94,827 women aged 45-80 with a BMI of 25 or above, presented at the ASCO conference in Chicago by University of Pennsylvania researchers, found that GLP-1 drugs like Ozempic, Wegovy, and Mounjaro were associated with a roughly 30% lower risk of breast cancer (1.7% of users vs 2.6% of non-users diagnosed), with lead author Professor Elizabeth McDonald calling for a large-scale clinical trial to establish causality.